Tag: Orencia

As of late 2025, there is no generic version of Orencia (abatacept) or a commercially approved biosimilar available on the market. This is primarily because Orencia is a complex biologic medication, and the process for creating and approving biosimilar alternatives is more complex and lengthy than for traditional generic drugs.

Abatacept, a selective T-cell costimulation modulator, is a crucial biologic therapy for autoimmune conditions like rheumatoid arthritis and psoriatic arthritis. For eligible patients, understanding **how is abatacept administered?** is essential, as the medication is available in two distinct forms—intravenous infusion and subcutaneous injection—each with its own procedure and schedule. The availability of these options allows for personalized treatment plans based on a patient's medical needs and lifestyle.